Shu-Hsing Cheng to Adult
This is a "connection" page, showing publications Shu-Hsing Cheng has written about Adult.
Connection Strength
0.068
-
Multiple types of human papillomavirus infection and anal precancerous lesions in HIV-infected men in Taiwan: a cross-sectional study. BMJ Open. 2018 01 27; 8(1):e019894.
Score: 0.012
-
National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2017-2020. J Glob Antimicrob Resist. 2021 09; 26:308-316.
Score: 0.004
-
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021 04 15; 12(1):2349.
Score: 0.004
-
Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. PLoS Pathog. 2021 02; 17(2):e1009352.
Score: 0.004
-
Multicenter evaluation of four immunoassays for the performance of early diagnosis of COVID-19 and assessment of antibody responses of patients with pneumonia in Taiwan. J Microbiol Immunol Infect. 2021 Oct; 54(5):816-829.
Score: 0.004
-
Clinical validation of an automated reverse transcription-insulated isothermal PCR assay for the detection of severe acute respiratory syndrome coronavirus 2. J Microbiol Immunol Infect. 2021 Jun; 54(3):522-526.
Score: 0.004
-
A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). PLoS One. 2020; 15(12):e0242763.
Score: 0.004
-
Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan. Emerg Microbes Infect. 2020 Dec; 9(1):2157-2168.
Score: 0.004
-
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat Struct Mol Biol. 2020 10; 27(10):950-958.
Score: 0.004
-
A case of transient existence of SARS-CoV-2 RNA in the respiratory tract with the absence of anti-SARS-CoV-2 antibody response. Int J Infect Dis. 2020 Jul; 96:464-466.
Score: 0.004
-
Early Seroreversion After 2 Doses of Hepatitis A Vaccination in Human Immunodeficiency Virus-Positive Patients: Incidence and Associated Factors. Hepatology. 2019 08; 70(2):465-475.
Score: 0.003
-
Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings. J Microbiol Immunol Infect. 2019 Aug; 52(4):556-562.
Score: 0.003
-
Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan. PLoS One. 2018; 13(3):e0194149.
Score: 0.003
-
Evolution of hepatitis A virus seroprevalence among HIV-positive adults in Taiwan. PLoS One. 2017; 12(10):e0186338.
Score: 0.003
-
Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up. PLoS One. 2017; 12(6):e0179870.
Score: 0.003
-
Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan. PLoS One. 2017; 12(2):e0171596.
Score: 0.003
-
Skin rash related to once-daily boosted darunavir-containing antiretroviral therapy in HIV-infected Taiwanese: incidence and associated factor. J Infect Chemother. 2014 Aug; 20(8):465-70.
Score: 0.002